DCGO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Rule-based valuation (P/E + Graham).
- Insufficient data for clear positives.
Rule-based growth outlook.
- Insufficient data for clear positives.
- Revenue is contracting.
Historical performance + price trend: Shares moved -94.3% over 5Y and -77.6% over 1Y.
- Insufficient data for clear positives.
- ROE only -89.0%.
- Thin profit margins.
Balance sheet & liquidity (Z-Score: N/A).
- Low D/E ratio (0.23).
Dividend policy fallback.
- Insufficient data for clear positives.
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for DCGO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
DCGO
DocGo Inc.
Primary
|
-94.3% | -93.1% | -77.6% | -55.1% | -15.2% | -9.4% |
|
BTMD
biote Corp.
Peer
|
-85.2% | -74.7% | -54.1% | -47.5% | -16.8% | +10.4% |
|
ATHE
Alterity Therapeutics Limited
Peer
|
-80.8% | -8.5% | +6.3% | -45.8% | +14.5% | +2.9% |
|
ALGS
Aligos Therapeutics, Inc.
Peer
|
-98.8% | -77.7% | -26.4% | -25.8% | +1.5% | +8.4% |
|
ARAY
Accuray Incorporated
Peer
|
-93.2% | -87.0% | -78.7% | -76.4% | -27.4% | -24.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
DCGO
DocGo Inc.
|
BEARISH | $56.28M | - | -89.0% | -56.6% | $0.57 | |
|
BTMD
biote Corp.
|
NEUTRAL | $55.53M | 2.01 | -% | 14.1% | $1.49 | Compare |
|
ATHE
Alterity Therapeutics Limited
|
BEARISH | $64.35M | - | -43.2% | -223.3% | $3.55 | Compare |
|
ALGS
Aligos Therapeutics, Inc.
|
BEARISH | $46.58M | - | -196.9% | -% | $7.57 | Compare |
|
ARAY
Accuray Incorporated
|
BEARISH | $44.0M | - | -70.3% | -8.2% | $0.37 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | TENDLER ELY D | General Counsel | Sale | 16,850 | $15,334 |
| 2025-12-12 | TRAVERS JAMES M | Director | Stock Award | 150,000 | - |
| 2025-12-12 | BURDIEK MICHAEL J | Director | Stock Award | 150,000 | - |
| 2025-12-12 | TENDLER ELY D | General Counsel | Stock Award | 100,000 | - |
| 2025-12-12 | ROSENBERG NORMAN | Chief Financial Officer | Stock Award | 429,405 | - |
| 2025-12-12 | LEITE ETALVINA | Director | Stock Award | 150,000 | - |
| 2025-12-12 | SMEDRA IRA | Director | Stock Award | 150,000 | - |
| 2025-12-12 | SUGRUE STEPHEN | Officer | Stock Award | 321,055 | - |
| 2025-12-12 | BIENSTOCK LEE | Chief Executive Officer | Stock Award | 1,113,495 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning DCGO from our newsroom.